Penumbra, Inc. Announces the Retirement of Don Kassing
Penumbra, Inc. (NYSE: PEN), a renowned thrombectomy company, recently shared significant news regarding its Board of Directors. After an impressive 17 years of dedicated service, Don Kassing has announced his decision to retire from the board, effective this spring. His journey with Penumbra began back in 2008, and since 2015, he has held the important role of Presiding Director.
A Legacy of Leadership and Service
Adam Elsesser, the board chair and CEO of Penumbra, expressed immense gratitude for Kassing's invaluable contributions over the years. "We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Elsesser. Kassing's leadership has been instrumental in guiding the company as it expanded its mission, which centers on providing better health outcomes for patients worldwide.
Background of Don Kassing
Don Kassing's career spans multiple decades in education and the private sector. He served as the President Emeritus of San Jose State University, where he made a lasting impact from 2004 to 2008. Shortly after his presidency, he took on the role of Interim President, demonstrating his commitment to the institution's success. Kassing's experience also includes significant positions in administration and finance, honing his skills in leadership and strategic planning.
Before joining San Jose State University, he spent 18 years in higher education and 11 years in private industry. Notably, he worked for Caleres, Inc. for eight years in merchandising, marketing, and operations management. His early career also includes experience in corporate finance at General Motors Corporation, showcasing a diverse professional background that spans both academia and industry.
Advancements at Penumbra, Inc.
Penumbra, Inc. focuses on spearheading innovative medical technologies. The company develops groundbreaking treatments for designs that aid in challenging medical situations such as ischemic stroke, pulmonary embolism, and acute limb ischemia. Their specialized devices, particularly the computer-assisted vacuum thrombectomy (CAVT), illustrate their commitment to enhancing healthcare outcomes.
Through these advancements, Penumbra aims to support healthcare providers across more than 100 countries, improving patient outcomes, and ultimately, quality of life. Penumbra's outstanding portfolio and pioneering innovations underscore their mission to assist healthcare professionals in responding to complex medical challenges.
Looking Ahead
The decision of Don Kassing to retire marks a significant moment for Penumbra, yet it opens a new chapter for the company as it seeks to build on the foundational work established under his guidance. As Penumbra continues to innovate and grow, it remains dedicated to its mission of improving healthcare through cutting-edge solutions.
For anyone looking to keep up with Penumbra's latest developments, you can visit their official website for more information on their groundbreaking technologies and ongoing projects.
Frequently Asked Questions
Who is Don Kassing?
Don Kassing is a long-serving board member of Penumbra, Inc. with a significant background in academia and private industry.
What was Don Kassing's role at Penumbra, Inc.?
He served as a member of the Board of Directors and held the position of Presiding Director since 2015.
What is Penumbra, Inc. known for?
Penumbra, Inc. is known for being a leading company in thrombectomy technologies aimed at treating serious medical conditions.
Why is Don Kassing's retirement significant?
Kassing's retirement marks the end of an influential chapter for Penumbra, recognizing his contributions and leadership during his tenure.
Where can I find more information about Penumbra's advancements?
For updates on their latest technologies and initiatives, visit Penumbra's official website.
